Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Other financing activities (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Other financing activities for 6 consecutive years, with $102000.0 as the latest value for Q4 2025.

  • For Q4 2025, Other financing activities rose 54.55% year-over-year to $102000.0; the TTM value through Mar 2026 reached $170000.0, down 67.31%, while the annual FY2025 figure was $624000.0, 845.45% up from the prior year.
  • Other financing activities hit $102000.0 in Q4 2025 for Cartesian Therapeutics, up from $43000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $454000.0 in Q1 2025 and bottomed at $25000.0 in Q2 2025.
  • Average Other financing activities over 3 years is $133333.3, with a median of $84000.0 recorded in 2024.
  • On a YoY basis, Other financing activities climbed as much as 54.55% in 2025 and fell as far as 54.55% in 2025.
  • Cartesian Therapeutics' Other financing activities stood at $110000.0 in 2022, then tumbled by 40.0% to $66000.0 in 2024, then skyrocketed by 54.55% to $102000.0 in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $102000.0, $43000.0, and $25000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.